Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137


Inhibition of CK2 enhances UV-triggered apoptotic cell death in lung cancer cell lines.

Zhao T, Jia H, Li L, Zhang G, Zhao M, Cheng Q, Zheng J, Li D.

Oncol Rep. 2013 Jul;30(1):377-84. doi: 10.3892/or.2013.2407. Epub 2013 Apr 18.


A CK2-dependent mechanism for degradation of the PML tumor suppressor.

Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Kaufman AJ, Singh B, Teruya-Feldstein J, Tempst P, Pandolfi PP.

Cell. 2006 Jul 28;126(2):269-83.


CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor.

Scaglioni PP, Yung TM, Choi S, Baldini C, Konstantinidou G, Pandolfi PP.

Mol Cell Biochem. 2008 Sep;316(1-2):149-54. doi: 10.1007/s11010-008-9812-7. Epub 2008 Jun 20. Erratum in: Mol Cell Biochem. 2009 Jul;327(1-2):279. Choi, S C [corrected to Choi, S].


Activation of protein kinase CK2 attenuates FOXO3a functioning in a PML-dependent manner: implications in human prostate cancer.

Chatterjee A, Chatterjee U, Ghosh MK.

Cell Death Dis. 2013 Mar 14;4:e543. doi: 10.1038/cddis.2013.63.


Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.

Quotti Tubi L, Gurrieri C, Brancalion A, Bonaldi L, Bertorelle R, Manni S, Pavan L, Lessi F, Zambello R, Trentin L, Adami F, Ruzzene M, Pinna LA, Semenzato G, Piazza F.

J Hematol Oncol. 2013 Oct 12;6:78. doi: 10.1186/1756-8722-6-78.


p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2.

Schneider CC, Hessenauer A, Montenarh M, Götz C.

Prostate. 2010 Feb 1;70(2):126-34. doi: 10.1002/pros.21044.


Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.

Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K, Trembley JH.

Breast Cancer Res. 2015;17:19. doi: 10.1186/s13058-015-0524-0. Epub 2015 Feb 11.


UV-induced apoptosis is mediated independent of caspase-9 in MCF-7 cells: a model for cytochrome c resistance.

Ferguson HA, Marietta PM, Van Den Berg CL.

J Biol Chem. 2003 Nov 14;278(46):45793-800. Epub 2003 Sep 3.


Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer.

Hung MS, Lin YC, Mao JH, Kim IJ, Xu Z, Yang CT, Jablons DM, You L.

PLoS One. 2010 Jul 2;5(7):e11418. doi: 10.1371/journal.pone.0011418.


CK2 inhibition induces apoptosis via the ER stress response.

Hessenauer A, Schneider CC, Götz C, Montenarh M.

Cell Signal. 2011 Jan;23(1):145-51. doi: 10.1016/j.cellsig.2010.08.014. Epub 2010 Aug 31.


Overexpression of PML induced apoptosis in bladder cancer cell by caspase dependent pathway.

Li L, He D, He H, Wang X, Zhang L, Luo Y, Nan X.

Cancer Lett. 2006 May 18;236(2):259-68. Epub 2005 Oct 10.


Protein kinase CK2 inhibition induces cell death via early impact on mitochondrial function.

Qaiser F, Trembley JH, Kren BT, Wu JJ, Naveed AK, Ahmed K.

J Cell Biochem. 2014 Dec;115(12):2103-15. doi: 10.1002/jcb.24887.


CK2 and PML: regulating the regulator.

Lallemand-Breitenbach V, de Thé H.

Cell. 2006 Jul 28;126(2):244-5.


Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription.

Tapia JC, Torres VA, Rodriguez DA, Leyton L, Quest AF.

Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15079-84. Epub 2006 Sep 27.


Poly(ADP-ribose) polymerase-1 inhibition by arsenite promotes the survival of cells with unrepaired DNA lesions induced by UV exposure.

Qin XJ, Liu W, Li YN, Sun X, Hai CX, Hudson LG, Liu KJ.

Toxicol Sci. 2012 May;127(1):120-9. doi: 10.1093/toxsci/kfs099. Epub 2012 Mar 2.


Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.

Toulany M, Kehlbach R, Florczak U, Sak A, Wang S, Chen J, Lobrich M, Rodemann HP.

Mol Cancer Ther. 2008 Jul;7(7):1772-81. doi: 10.1158/1535-7163.MCT-07-2200.

Supplemental Content

Support Center